Experimental HCV Drugs
Experimental HCV Drugs
ICAAC 2011: BMS-790052 plus Standard Therapy Cures Most Genotype 1 Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 19 September 2011 00:00
- Written by Liz Highleyman
Up to 83% of treatment-naive people with difficult-to-treat genotype 1 hepatitis C virus (HCV) infection achieved sustained virological response (SVR) with the experimental HCV NS5A inhibitor BMS-790052 plus pegylated interferon and ribavirin, according to data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.
Early Data on BMS-790052 HCV NS5A Inhibitor Published
- Details
- Category: HCV Treatment
- Published on Monday, 12 September 2011 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's experimental HCV NS5A inhibitor, BMS-790052, demonstrated potent antiviral activity, was well-tolerated, and pharmacokinetic parameters support once-daily dosing, according to a small 14-day proof-of-concept study described in the August 11, 2011, advance online edition of Hepatology.
TMC435 for Hepatitis C Phase 3 Studies Fully Enrolled, Company Says
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 06 September 2011 00:00
- Written by Medivir
Medivir announced last week that Phase 3 clinical trials of its investigational hepatitis C virus (HCV) protease inhibitor, TMC435 (initially developed by Tibotec/Janssen), are have completed enrollment and participants have begun receiving randomized treatment.
PSI-7977 with Standard Therapy Produces 91% Sustained Response
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 09 September 2011 00:00
- Written by Pharmasset
The experimental hepatitis C virus (HCV) nucleotide analog polymerase inhibitor PSI-7977, used in combination with pegylated interferon and ribavirin, demonstrated a 12-week sustained virological response rate of 91% for previously untreated genotype 1 chronic hepatitis C patients in the ongoing PROTON trial.
HCV Polymerase Inhibitor PSI-938 Gets Fast Track Status
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 August 2011 00:00
- Written by Pharmasset
The U.S. Food and Drug Administration (FDA) last week granted a "fast track" designation for PSI-938, an investigational nucleotide analog hepatitis C virus (HCV) polymerase inhibitor being developed by Pharmasset.
Web Design and Development by